Featured Research

from universities, journals, and other organizations

Mapping translation sites in the human genome

Date:
June 16, 2013
Source:
Arizona State University
Summary:
Scientists have produced the first genome-wide investigation of cap-independent translation, identifying thousands of mRNA sequences that act as Translation Enhancing Elements, which are RNA sequences upstream of the coding region that help recruit the ribosome to the translation start site.

John Chaput, a researcher in the Center for Evolutionary Medicine and Informatics at Arizona State University's Biodesign Institute.
Credit: The Biodesign Institute at Arizona State University

Because of their central importance to biology, proteins have been the focus of intense research, particularly the manner in which they are produced from genetically coded templates -- a process commonly known as translation. While the general mechanism of translation has been understood for some time, protein synthesis can initiate by more than one mechanism. One of the least well understood mechanisms is known as cap-independent translation.

Now, John Chaput and his colleagues at Arizona State University's Biodesign Institute have produced the first genome-wide investigation of cap-independent translation, identifying thousands of mRNA sequences that act as Translation Enhancing Elements (TEEs), which are RNA sequences upstream of the coding region that help recruit the ribosome to the translation start site.

The new study outlines a technique for mining whole genomes for sequences that initiate cap-independent translation within the vastness of the genome.

The research has important implications for the fundamental understanding of translation in living systems, as well as intriguing potential in the biomedical arena. (Many viral pathogens are known to use cap-independent translation to hijack and redirect cellular mechanisms to translate viral proteins.)

The lead author of the study is Brian P. Wellensiek, a senior scientist in Biodesign's Center for Evolutionary Medicine and Informatics. The group's results appear in the current issue of the journal Nature Methods.

During most protein synthesis in eukaryotic cells, cap-dependent translation dominates. The process begins after DNA is first transcribed into mRNA, with the aid of an enzyme polymerase. mRNA now forms the coded template from which the translated proteins will be generated. The mRNA code consists of sequences made from 4 nucleic acids, A, C, G & U, with each 3-letter grouping (known as a codon), corresponding to one amino acid in the protein being synthesized.

A key component in the translation process is the ribosome, which migrates along the single stranded mRNA, reading the codons as it goes. Before it can do this however, it must locate a special structure at the 5' end of the mRNA strand known as the cap. In normal cap-dependent translation, the ribosome is recruited to the 5' end of mRNA via a specialized cap-binding complex.

Cap-independent translation allows the ribosome to begin reading the mRNA message without having to first locate the 5' cap structure. Cap-independent translation occurs in eukaryotic cells during normal processes including mitosis and apoptosis (or programmed cell death). It is also a feature in many forms of viral translation, where the viral transcript is able to recruit the ribosome and co-opt its function to preferentially translate viral RNA.

In the current study, Chaput designed an in vitro selection strategy to identify human genome sequences that initiate cap-independent translation. The technique is able to select candidates from a pool of trillions of genomic fragments. Once a set of sequences was identified as translation enhancing elements, they were shown to function effectively in both cell-free and cellular translation systems.

As Chaput explains, most research on cap-independent translation has been conducted using RNA fragments derived from viruses. "These RNA molecules will fold into shapes that appear to mimic some of the initiation factors that that you would find in eukaryotic translation," he says. More recently, similar RNA molecules have been identified in cellular systems, though the sequences tend to be much shorter and function in a different manner.

Chaput's method of studying such sequences on a genome-wide scale involves first generating a DNA library of the entire human genome. Using enzymes, the genome is cut into random fragments of around 200 base pairs each. These sequences are then transcribed into mRNA.

Applying a technique known as mRNA display, the fragments are tagged in specific way, such that amino acid sequences resulting from successful translation events remain bound to the mRNA fragments that generated them. "Essentially, what we're doing is taking a library of human mRNA and tagging those sequences that act as translation enhancing elements," Chaput says. Those sequences bearing an attached peptide affinity tag can then be separated out from the remaining untranslated sequences, reverse transcribed, amplified using PCR technology and subjected to subsequent rounds of selection.

The sequences were later mapped onto the human genome. As expected, the complete library of sequences used at the start of the experiments mapped fairly evenly across the genome. But the sequences selected via mRNA display as translation enhancing elements tended to cluster in non-coding regions of the genome. The authors speculate that such sequences may have been evolutionarily selected against, as they have the potential to disrupt normal cap-dependent translation.

Roughly 20 percent of the translation enhancing elements functioned as internal ribosomal initiation sites, again turning up primarily in non-coding genomic regions. The origin of these sequences remains mysterious. It is conceivable that they were surreptitiously brought on board as a result of human interaction with different types of viruses.

Once Chaput's group had acquired a library of 250 distinct translation enhancing elements through selection using mRNA display, the sequences were screened for translation enhancing activity, which was quantified using a light based assay employing a luciferase reporter molecule.

By measuring levels of luciferase, the enhancement of each sequence could be assessed relative to background noise, with the better translation enhancing elements displaying 50-100 fold enhancement (and some as much as 1000-fold enhancement). The next step was to determine which of these sequences could function as internal ribosomal initiation sites.

To do this, the same 250 sequences were inserted into a vector bearing a hairpin structure. As Chaput explains: "If the ribosome latched onto the 5' end, it would hit that hairpin and would fall off. However if the ribosome skipped the hairpin and recognized the sequence on the other side of the hairpin independently and translated it, that's an indication that the sequence is functioning as an internal ribosomal initiation site." Both assays (for translation enhancement and internal ribosomal initiation) were validated under cell-free conditions and in human cells, using a vaccinia virus vector.

A study of this scope is possible thanks to innovative techniques for in vitro selection (such as mRNA display), as well as a revolutionary technology permitting massively parallel RNA sequencing (known as deep sequencing), which provides unprecedented speed and read accuracy.

Much remains to be learned about atypical translation processes. The mechanism of action for translation enhancing elements is still obscure, particularly in the case of internal ribosomal initiation sites. Similarly, the particular gene products that may result from cap-independent translation have yet to be identified and characterized.


Story Source:

The above story is based on materials provided by Arizona State University. The original article was written by Richard Harth. Note: Materials may be edited for content and length.


Journal Reference:

  1. Brian P Wellensiek, Andrew C Larsen, Bret Stephens, Kim Kukurba, Karl Waern, Natalia Briones, Li Liu, Michael Snyder, Bertram L Jacobs, Sudhir Kumar, John C Chaput. Genome-wide profiling of human cap-independent translation-enhancing elements. Nature Methods, 2013; DOI: 10.1038/nmeth.2522

Cite This Page:

Arizona State University. "Mapping translation sites in the human genome." ScienceDaily. ScienceDaily, 16 June 2013. <www.sciencedaily.com/releases/2013/06/130616155211.htm>.
Arizona State University. (2013, June 16). Mapping translation sites in the human genome. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2013/06/130616155211.htm
Arizona State University. "Mapping translation sites in the human genome." ScienceDaily. www.sciencedaily.com/releases/2013/06/130616155211.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins